Physician profile
Alan M Birnbaum
NPI 1912937186
$2,287.32
in general payments reported to CMS, 2019-2025
37 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $227 · 2022: $97.54 · 2023: $267 · 2024: $109 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $182.59 | 2019-2020 | |
| Nevro Corp. | $173.50 | 2023 | Senza |
| Lilly USA, LLC | $165.76 | 2019 | |
| Eisai INC. | $156.50 | 2019 | |
| Abiomed | $143.07 | 2020 | |
| Pfizer INC. | $133.20 | 2019-2025 | |
| Braeburn INC. | $125.54 | 2025 | Brixadi |
| Acadia Pharmaceuticals INC | $124.98 | 2019 | |
| Abbvie INC. | $117.71 | 2019-2023 | Ubrelvy, Qulipta |
| Penumbra, INC. | $109.36 | 2024 | Penumbra System |
| Medtronic, INC. | $97.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $76.21 | 2019 | |
| Pacira Therapeutics, INC. | $74.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.82 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $41.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $41.07 | 2019 | |
| Boston Scientific Corporation | $40.82 | 2019 | |
| Novo Nordisk INC | $32.16 | 2019 | |
| Abbott Laboratories | $30.13 | 2019 | |
| Lundbeck LLC | $28.94 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.23 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $22.84 | 2019 | |
| Livanova USA, INC. | $22.75 | 2019 | |
| Sanofi Pasteur INC. | $18.65 | 2019 | |
| Vertiflex, INC. | $15.96 | 2019 | |
| Amarin Pharma, INC. | $15.40 | 2019 | |
| Daiichi Sankyo INC. | $14.41 | 2019 | |
| Edwards Lifesciences Corporation | $13.19 | 2019 | |
| Ucb, INC. | $13.15 | 2019 | |
| Allergan, INC. | $12.53 | 2019 | |
| Akcea Therapeutics, INC. | $12.21 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.00 | 2019 | |
| Nabriva Therapeutics, Plc | $11.20 | 2020 | |
| Ironwood Pharmaceuticals, INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.